<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1479">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05141903</url>
  </required_header>
  <id_info>
    <org_study_id>21-CT-003</org_study_id>
    <nct_id>NCT05141903</nct_id>
  </id_info>
  <brief_title>Dietary Supplement With and Without a Probiotic and/or Antibiotic</brief_title>
  <official_title>Dietary Study of a Complex Oligosaccharide With and Without a Probiotic Following Antibiotic Treatment in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prolacta Bioscience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prolacta Bioscience</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Complex oligosaccharides can alter the gut microbiome by aiding in the growth of certain&#xD;
      organisms, and possibly, inhibiting others. The synergy with a probiotic may enhance&#xD;
      gastrointestinal colonization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate the synergy of the use of a complex oligosaccharide with and without&#xD;
      a probiotic on the human microbiome in healthy volunteers who have received antibiotics. The&#xD;
      combination should support general gastrointestinal health.&#xD;
&#xD;
      This study is a multi-dose randomized cohort trial using 10 subjects per cohort for a total&#xD;
      of 50 healthy adult volunteers ages 18-75.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2021</start_date>
  <completion_date type="Anticipated">June 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 21, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcomes</measure>
    <time_frame>35 days</time_frame>
    <description>Evaluation of the changes in microbiome species abundance and diversity from baseline until end of study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcomes</measure>
    <time_frame>35 days</time_frame>
    <description>Blood parameters, such as cytokine levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seconday Outcomes</measure>
    <time_frame>35 days</time_frame>
    <description>Safety assessment</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <description>Antibiotic conditioning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <description>Antibiotic conditioning, Dose ranging of dietary supplement with and probiotic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <description>Antibiotic conditioning, Dose ranging of dietary supplement with and probiotic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <description>Antibiotic conditioning, Dose ranging of dietary supplement with and probiotic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5</arm_group_label>
    <description>Antibiotic conditioning and probiotic treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary supplement, probiotic, antibiotic conditioning -all groups</intervention_name>
    <description>Dietary supplement, probiotic, antibiotic conditioning -all groups</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, urine, and stool&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy Adults, ages 18-75.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults between the ages of 18-75 years (subjects must be 18-75 at the time of&#xD;
             consent) who can provide proof of vaccination against SARS-CoV-2. Proof may be a&#xD;
             physical or electronic record of vaccination or self-attestation (to include&#xD;
             approximate vaccination date and manufacturer of vaccine) if a copy of the vaccination&#xD;
             record is not available&#xD;
&#xD;
          -  Subjects must have a BMI of 18 - 30 at screening visit&#xD;
&#xD;
          -  Willingness to complete study specific questionnaires&#xD;
&#xD;
          -  Willingness to complete journal to record IP dosing times, Bristol stool scores, and&#xD;
             IP flavor questionnaires&#xD;
&#xD;
          -  Willingness to complete all study procedures, clinic visits, and provide required&#xD;
             biospecimen samples&#xD;
&#xD;
          -  Willingness to collect and process stool samples at home and transport stool samples&#xD;
             to clinic&#xD;
&#xD;
          -  Sexually active females of child-bearing potential must agree to use highly effective&#xD;
             methods of contraception during heterosexual intercourse throughout the study period&#xD;
             and for three days following discontinuation of IP, whichever comes later. Examples of&#xD;
             highly effective methods include the use of two forms of contraception with one being&#xD;
             an effective barrier method (e.g., a condom and spermicide used together), or have a&#xD;
             vasectomised partner. Abstinence is acceptable as a life-style choice. Female subjects&#xD;
             who utilize hormonal contraceptives as one of their birth control methods must have&#xD;
             used the same method for at least 3 months before study dosing&#xD;
&#xD;
          -  Provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a BMI of 17 or less or 31 or greater are excluded&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding, or intend to become pregnant during the&#xD;
             course of this study&#xD;
&#xD;
          -  Subjects who intend to take a probiotic during the study&#xD;
&#xD;
          -  Subjects with self-reported diarrhea on day 1 prior to dosing, whereby diarrhea is&#xD;
             defined as two or more episodes of watery and/or unformed stool within 24 hours&#xD;
&#xD;
          -  Alcohol or drug abuse during the last 12 months, including passing a screen for drugs&#xD;
             of abuse at screening and day 1 of the study&#xD;
&#xD;
          -  Unstable medical condition, in the opinion of the investigator&#xD;
&#xD;
          -  Subject with a history of allergy to the study antibiotics&#xD;
&#xD;
          -  Clinically significant abnormal laboratory test results at screening&#xD;
&#xD;
          -  Subjects who are unable or unwilling to provide stool samples on a regular basis as&#xD;
             per study protocol&#xD;
&#xD;
          -  Participation in a clinical research trial within 30 days prior to screening&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Any condition which may preclude subject's ability to comply with and complete the&#xD;
             study or may pose a risk to the health of the subject&#xD;
&#xD;
          -  Known carriers of C. difficile prior to study start, as determined by qPCR of stool&#xD;
&#xD;
          -  Known carriers of vancomycin-resistant enterococci (VRE) prior to study start, as&#xD;
             determined by stool culture&#xD;
&#xD;
          -  Subjects with history of lactose intolerance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>David Rechtman, MD</last_name>
    <phone>(888) 776-5228</phone>
    <email>info@prolacta.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Lee, PHD</last_name>
    <phone>(888) 776-5228</phone>
    <email>info@prolacta.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Altasciences</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-252-0700</phone>
      <email>contact@altasciences.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

